Moderna, Tabuk Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi Arabia

 -Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group), a leading Saudi pharmaceuticals company, today announced an agreement to commercialize the Moderna COVID-19 Vaccine and future variant-specific booster candidates in Saudi Arabia.

Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine in Saudi Arabia. Beyond the Moderna COVID-19 Vaccine and Moderna’s updated variant booster candidates, the agreement also gives Tabuk the possibility to discuss opportunities to distribute other Moderna mRNA products if authorized in the future.

https://www.businesswire.com/news/home/20210611005274/en/Moderna-and-Tabuk-Pharmaceuticals-Partner-to-Commercialize-Moderna%E2%80%99s-COVID-19-Vaccine-in-Saudi-Arabia